NCT03913559 2026-02-12
Inotuzumab Ozogamicin for Children With MRD Positive CD22+ Lymphoblastic Leukemia
St. Jude Children's Research Hospital
Phase 2 Terminated
St. Jude Children's Research Hospital
Mayo Clinic
Sanofi
Oral Defense, LLC
Stanford University
University of South Florida
Duke University